A Multi-center, Single-arm, Interventional Phase 4 Study to Evaluate a Treat and Extend Regimen of Intravitreal Aflibercept for Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion

Trial Profile

A Multi-center, Single-arm, Interventional Phase 4 Study to Evaluate a Treat and Extend Regimen of Intravitreal Aflibercept for Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Central retinal vein occlusion; Retinal oedema
  • Focus Therapeutic Use
  • Acronyms CENTERA
  • Sponsors Bayer
  • Most Recent Events

    • 25 Aug 2016 Planned End Date changed from 1 May 2019 to 1 Aug 2019.
    • 25 Aug 2016 Planned primary completion date changed from 1 May 2019 to 1 Aug 2019.
    • 25 Aug 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top